📊 HUM Key Takeaways
Is Humana Inc. (HUM) a Good Investment?
Humana demonstrates solid financial health with strong liquidity ratios (2.0x current ratio) and low leverage (0.70x debt/equity), supported by exceptional interest coverage of 17.0x. However, the business faces profitability headwinds evidenced by declining net income (-1.2% YoY), extremely thin net margins (0.9%), and weak free cash flow conversion (0.3% FCF margin), suggesting operational challenges in the managed care business despite substantial revenue scale.
Humana’s fundamentals show a financially stable but low-margin business: leverage and liquidity look manageable, and interest coverage is strong, but profitability remains thin for the revenue base. Growth quality is questionable because reported revenue surged while net income and EPS declined slightly, and free cash flow conversion was very weak, suggesting the topline expansion is not translating into stronger underlying earnings power.
Why Buy Humana Inc. Stock? HUM Key Strengths
- Strong balance sheet with manageable debt levels (0.70x debt/equity) and substantial cash position (4.2B)
- Excellent liquidity position with 2.00x current and quick ratios indicating short-term financial flexibility
- Exceptional interest coverage ratio of 17.0x demonstrates strong ability to service debt obligations
- Massive scale with 129.7B in revenue positioning as a major player in healthcare services
- Solid balance sheet support with a 2.00x current ratio, 0.70x debt-to-equity, and strong 17.0x interest coverage
- Positive net income and free cash flow, indicating the business remains profitable and cash-generative despite sector pressure
- Large equity base and moderate ROE/ROA suggest adequate capital support and operational resilience
HUM Stock Risks: Humana Inc. Investment Risks
- Declining profitability with net income down 1.2% YoY despite massive revenue base, indicating margin compression
- Extremely thin net profit margin of 0.9% leaves minimal buffer for operational disruptions or adverse developments
- Weak free cash flow generation relative to revenue scale (0.3% FCF margin) limits capital deployment flexibility
- Low return metrics (ROE 6.7%, ROA 2.4%) suggest inefficient capital utilization relative to asset base
- Managed care sector exposure to regulatory and reimbursement rate pressures
- Very thin margins, with 2.1% operating margin and 0.9% net margin, leave limited room for execution mistakes or medical cost pressure
- Poor growth quality as revenue jumped sharply but net income fell 1.2% and diluted EPS fell 1.4%
- Free cash flow is weak relative to revenue, with only a 0.3% FCF margin, which limits financial flexibility if operating conditions worsen
Key Metrics to Watch
- Net profit margin trend and underlying cost inflation in medical services
- Free cash flow generation and sustainability of capital expenditure levels
- Operating margin trajectory in core insurance segments
- Medical loss ratio trends and reimbursement rate sustainability
- Operating margin and medical cost trend
- Operating cash flow and free cash flow conversion
Humana Inc. (HUM) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The relatively thin 0.3% FCF margin may limit capital allocation flexibility. Strong liquidity with a 2.00x current ratio provides a solid financial cushion.
HUM Profit Margin, ROE & Profitability Analysis
HUM vs Healthcare Sector: How Humana Inc. Compares
How Humana Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Humana Inc. Stock Overvalued? HUM Valuation Analysis 2026
Based on fundamental analysis, Humana Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Humana Inc. Balance Sheet: HUM Debt, Cash & Liquidity
HUM Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Humana Inc.'s revenue has grown significantly by 91% over the 5-year period, indicating strong business expansion. The most recent EPS of $20.00 reflects profitable operations.
HUM Revenue Growth, EPS Growth & YoY Performance
HUM Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $1.1B | $195.0M | $1.62 |
| Q2 2025 | $1.1B | $545.0M | $4.51 |
| Q1 2025 | $1.1B | $741.0M | $6.11 |
| Q3 2024 | $1.0B | $480.0M | $3.98 |
| Q2 2024 | $978.0M | $679.0M | $5.62 |
| Q1 2024 | $999.0M | $741.0M | $6.11 |
| Q3 2023 | $1.0B | $832.0M | $6.71 |
| Q2 2023 | $978.0M | $696.0M | $5.48 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Humana Inc. Dividends, Buybacks & Capital Allocation
HUM SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Humana Inc. (CIK: 0000049071)
📋 Recent SEC Filings
❓ Frequently Asked Questions about HUM
What is the AI rating for HUM?
Humana Inc. (HUM) has a Combined AI Rating of HOLD from Claude (HOLD) and ChatGPT (HOLD) with 70% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are HUM's key strengths?
Claude: Strong balance sheet with manageable debt levels (0.70x debt/equity) and substantial cash position (4.2B). Excellent liquidity position with 2.00x current and quick ratios indicating short-term financial flexibility. ChatGPT: Solid balance sheet support with a 2.00x current ratio, 0.70x debt-to-equity, and strong 17.0x interest coverage. Positive net income and free cash flow, indicating the business remains profitable and cash-generative despite sector pressure.
What are the risks of investing in HUM?
Claude: Declining profitability with net income down 1.2% YoY despite massive revenue base, indicating margin compression. Extremely thin net profit margin of 0.9% leaves minimal buffer for operational disruptions or adverse developments. ChatGPT: Very thin margins, with 2.1% operating margin and 0.9% net margin, leave limited room for execution mistakes or medical cost pressure. Poor growth quality as revenue jumped sharply but net income fell 1.2% and diluted EPS fell 1.4%.
What is HUM's revenue and growth?
Humana Inc. reported revenue of $129.7B.
Does HUM pay dividends?
Humana Inc. pays dividends, with $430.0M distributed to shareholders in the trailing twelve months.
Where can I find HUM SEC filings?
Official SEC filings for Humana Inc. (CIK: 0000049071) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is HUM's EPS?
Humana Inc. has a diluted EPS of $9.84.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is HUM a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Humana Inc. has a HOLD rating with 70% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is HUM stock overvalued or undervalued?
Valuation metrics for HUM: ROE of 6.7% (sector avg: 15%), net margin of 0.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy HUM stock in 2026?
Our dual AI analysis gives Humana Inc. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is HUM's free cash flow?
Humana Inc.'s operating cash flow is $921.0M, with capital expenditures of $546.0M. FCF margin is 0.3%.
How does HUM compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 0.9% (avg: 12%), ROE 6.7% (avg: 15%), current ratio 2.00 (avg: 2).